Compare INSG & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSG | TNYA |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.1M | 171.4M |
| IPO Year | 2000 | 2021 |
| Metric | INSG | TNYA |
|---|---|---|
| Price | $10.52 | $0.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $15.33 | $5.33 |
| AVG Volume (30 Days) | 448.1K | ★ 3.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $313,832,000.00 | N/A |
| Revenue This Year | $16.21 | N/A |
| Revenue Next Year | $13.28 | N/A |
| P/E Ratio | $15.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.28 | $0.53 |
| 52 Week High | $21.90 | $2.35 |
| Indicator | INSG | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 40.35 |
| Support Level | $9.35 | $0.65 |
| Resistance Level | $12.61 | $0.82 |
| Average True Range (ATR) | 1.23 | 0.06 |
| MACD | -0.29 | -0.02 |
| Stochastic Oscillator | 16.10 | 10.67 |
Inseego Corp is involved in the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things, and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by application software and cloud services designed to enable customers to analyze data insights and configure and manage their hardware easily. It generates maximum revenue from the United States and Canada. The company also has a presence in Europe (including the United Kingdom).
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.